University of Münster
CRIS@UM
DE | EN
Profile picture of Dr. rer. nat. Thomas Viel

Dr. rer. nat. Thomas Viel

No current affiliations available for this person. The person is no longer active at the university.

Curriculum Vitae (CV)

Research Focus

  • Molecular Imaging for the assessment of new therapies, including gene therapies, for the treatment of glioma
    Designing viral vectors expressing shRNA against MGMT, a key protein involved in the resistance of gliomas against alkylating chemotherapyFollowing anti-prolidferative treatment efficacies in gliomas using PET and MRI
  • Molecular imaging Imaging of neuro-inflammation in neurodegenerative diseases

Academic Education

10/2004 - 01/2008Ph.D. in Molecular Biology and Imaging (CEA/I2BM, INSERM U803, Orsay, France) Study of the effect of siRNAs modifications on their activity / Study of the biodistribution and pharmacokinetics of the modified siRNAs using PET imaging and of their in vivo activity using BLI / Study using FRI of a tumour specific protein as targeting reagent

Work Experience

since 07/2010Postdoc at the European Institute for Molecular Imaging (EIMI)
07/2008 - 07/2010Post-doc in the Max Planck Institute for Neurological Research (Cologne, Germany)

Publications

Combined PET imaging of the inflammatory tumor microenvironment identifies margins of unique radiotracer uptake
Zinnhardt B, Pigeon H, Thézé B, Viel T, Wachsmuth L, Fricke IB, Schelhaas S, Honold L, Schwegmann K, Wagner S, Faust A, Faber C, Kuhlmann MT, Hermann S, Schäfers M, Winkeler A, Jacobs AH (2017)
In: Cancer Research, 77(8), 1831-1841. doi:10.1158/0008-5472.CAN-16-2628
Research article (journal) | Peer reviewed | Published
Preclinical evidence that 3′-deoxy-3′-[18F]fluorothymidine PET can visualize recovery of hematopoiesis after gemcitabine chemotherapy.
Schelhaas S, Held A, Bäumer N, Viel T, Hermann S, Müller-Tidow C, Jacobs A. (2016)
In: Cancer Research, 76(24), 7089-7095. doi:10.1158/0008-5472.CAN-16-1478
Research article (journal) | Peer reviewed | Published
6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
Fricke I, Viel T, Worlitzer M, Collmann F, Vrachimis A, Faust A, Wachsmuth L, Faber C, Dollé F, Kuhlmann M, Schäfers K, Hermann S, Schwamborn J, Jacobs A. (2016)
In: European Journal of Neuroscience, 43(10), 1352-1365. doi:10.1111/ejn.13232
Research article (journal) | Peer reviewed | Published
Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
O’Halloran P, Viel T, Murray D, Wachsmuth L, Schwegmann K, Wagner S, Kopka K, Jarzabek M, Dicker P, Hermann S, Faber C, Klasen T, Schäfers M, O’Brien D, Prehn J, Jacobs A, Byrne A. (2016)
In: European Journal of Nuclear Medicine and Molecular Imaging, 43(9), 1673-1683. doi:10.1007/s00259-016-3343-3
Research article (journal) | Peer reviewed | Published
Multimodal imaging reveals temporal and spatial microglia and matrix-metalloproteinase (MMP) activity after experimental stroke
Zinnhardt B, Viel T, Wachsmuth L, Vrachimis A, Wagner St, Breyholz HJ, Faust A, Hermann S, Kopka K, Faber C, Dollé F, Pappata S, Planas AM, Tavitian B, Schäfers M, Sorokin L, Kuhlmann M, Jacobs AH  (2015)
In: Journal of Cerebral Blood Flow and Metabolism, 35(11), 1711-1721. doi:10.1038/jcbfm.2015.149
Research article (journal) | Peer reviewed | Published
Show all publications (8)